Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. (Q34587751)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. |
scientific article |
Statements
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 (English)
Charles D Blanke
Cathryn Rankin
George D Demetri
Christopher W Ryan
Robert S Benjamin
A Kevin Raymond
Vivien H C Bramwell
Laurence H Baker
Michael Tanaka
J Randolph Hecht
Christopher D M Fletcher
John J Crowley
Ernest C Borden
Margaret von Mehren
1 February 2008